Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AVTE

AVTE - Aerovate Therapeutics, Inc. Stock Price, Fair Value and News

22.92USD-0.85 (-3.58%)Market Closed
Watchlist

Market Summary

USD22.92-0.85
Market Closed
-3.58%

AVTE Alerts

  • CITADEL ADVISORS LLC reported owning 0% of AVTE [2024-02-14]

AVTE Stock Price

View Fullscreen

AVTE RSI Chart

AVTE Valuation

Market Cap

657.7M

Price/Earnings (Trailing)

-9.38

EV/EBITDA

-9.44

Price/Free Cashflow

-11.55

MarketCap/EBT

-10.04

AVTE Price/Earnings (Trailing)

AVTE Profitability

Return on Equity

-55.78%

Return on Assets

-49.78%

Free Cashflow Yield

-8.66%

AVTE Fundamentals

AVTE Earnings

Earnings (TTM)

-70.1M

Earnings Growth (Yr)

-43.97%

Earnings Growth (Qtr)

-2.83%

Breaking Down AVTE Revenue

Last 7 days

-2.5%

Last 30 days

4.1%

Last 90 days

44.3%

Trailing 12 Months

-13.2%

How does AVTE drawdown profile look like?

AVTE Financial Health

Current Ratio

9.34

AVTE Investor Care

Shares Dilution (1Y)

12.45%

Diluted EPS (TTM)

-2.75

Tracking the Latest Insider Buys and Sells of Aerovate Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 20, 2024
gillies hunter
acquired
6,070
1.74
3,489
chief medical officer
Feb 20, 2024
gillies hunter
sold
-70,574
20.2277
-3,489
chief medical officer
Feb 05, 2024
niven ralph
sold
-80,249
17.4455
-4,600
chief scientific officer
Feb 05, 2024
niven ralph
acquired
9,284
2.01826
4,600
chief scientific officer
Jan 17, 2024
gillies hunter
acquired
6,960
1.74
4,000
chief medical officer
Jan 17, 2024
gillies hunter
sold
-78,000
19.5
-4,000
chief medical officer
Jan 05, 2024
niven ralph
acquired
9,284
2.01826
4,600
chief scientific officer
Jan 05, 2024
niven ralph
sold
-88,115
19.1556
-4,600
chief scientific officer
Dec 27, 2023
gillies hunter
sold
-3,062
24.5
-125
chief medical officer
Dec 27, 2023
gillies hunter
acquired
267
2.14
125
chief medical officer

1–10 of 50

Which funds bought or sold AVTE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
new
-
275,588
275,588
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-78.34
-66,680
37,701
-%
Feb 15, 2024
BARCLAYS PLC
added
300
296,000
348,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
296,589
296,589
-%
Feb 15, 2024
Nantahala Capital Management, LLC
added
91.97
2,838,020
4,127,170
0.12%
Feb 14, 2024
Ameritas Investment Partners, Inc.
unchanged
-
6,994
17,470
-%
Feb 14, 2024
Point72 Asset Management, L.P.
new
-
9,990,560
9,990,560
0.02%
Feb 14, 2024
ALLIANCEBERNSTEIN L.P.
added
5.22
127,506
296,453
-%
Feb 14, 2024
Royal Bank of Canada
added
148
60,000
79,000
-%
Feb 14, 2024
VANGUARD GROUP INC
added
4.63
6,055,370
14,185,200
-%

1–10 of 50

Are Funds Buying or Selling AVTE?

Are funds buying AVTE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AVTE
No. of Funds

Unveiling Aerovate Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 20, 2024
sofinnova venture partners x, l.p.
13.6%
3,758,686
SC 13D/A
Feb 14, 2024
baker bros. advisors lp
6.1%
1,680,517
SC 13G/A
Feb 14, 2024
citadel advisors llc
0.0%
6
SC 13G/A
Feb 14, 2024
cormorant asset management, lp
0.00%
0
SC 13G/A
Feb 09, 2024
tcg crossover gp i, llc
8.0%
2,201,274
SC 13G
Jun 27, 2023
ra capital management, l.p.
30%
8,293,148
SC 13D/A
Feb 14, 2023
baker bros. advisors lp
8.0%
1,976,868
SC 13G/A
Feb 14, 2023
citadel advisors llc
6.4%
6
SC 13G/A
Feb 14, 2023
cormorant asset management, lp
3.03%
745,436
SC 13G/A
Feb 06, 2023
sofinnova venture partners x, l.p.
15.3%
3,758,686
SC 13D/A

Recent SEC filings of Aerovate Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Feb 27, 2024
4
Insider Trading
Feb 23, 2024
144
Notice of Insider Sale Intent
Feb 22, 2024
4
Insider Trading
Feb 20, 2024
144
Notice of Insider Sale Intent
Feb 20, 2024
SC 13D/A
13D - Major Acquisition
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G
Major Ownership Report
Feb 07, 2024
4
Insider Trading

Peers (Alternatives to Aerovate Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.5B
1.8B
-23.99% -31.71%
-44.39
10.69
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.64
7.11
15.42% 18.43%
13.5B
3.7B
-7.62% -26.87%
22.54
3.64
8.87% 75.42%
MID-CAP
8.2B
396.6M
-2.06% 34.31%
-15.49
20.64
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.3B
631.9M
-12.60% 32.37%
-29.08
6.85
23.54% 31.53%
4.0B
270.6M
8.92% 47.81%
-16.63
14.71
440.80% -27.84%
3.9B
240.7M
-19.08% -10.99%
-13.01
16.04
-1.03% -92.09%
SMALL-CAP
1.6B
348.4M
-3.38% -9.50%
25.02
4.46
81.69% -7.29%
521.5M
1.0B
-9.17% -57.89%
-0.95
0.5
-43.15% 58.48%
192.2M
4.9M
-14.18% -58.18%
-1.17
39.32
-57.57% 50.48%
123.2M
881.7K
289.54% 381.25%
-2.6
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aerovate Therapeutics, Inc. News

Latest updates
MarketBeat24 Feb 202409:01 pm
MarketBeat06 Feb 202408:00 am

Aerovate Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-9.6%14115612413514815616717518462.00--
  Current Assets-9.8%13815212113114515316617418359.00-5.00
    Cash Equivalents-47.2%32.0061.0027.0022.0022.0027.0028.0054.0018159.00-5.00
  Net PPE29.0%0.000.000.000.000.000.000.000.000.000.00-0.00
Liabilities9.6%15.0014.0011.009.009.005.005.003.004.003.003.002.00
  Current Liabilities10.8%15.0013.0011.008.008.004.005.003.004.004.00-2.00
Shareholder's Equity-11.4%1261421131271391511621721800.000.000.00
  Retained Earnings-15.8%-143-123-104-87.90-72.88-59.29-47.30-36.39-28.17-21.98--13.41
  Additional Paid-In Capital1.3%2692662182152132112102092080.00-0.00
Shares Outstanding0.2%28.0028.0025.0025.0024.0024.0024.0024.0024.00--0.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations-4.5%-15,611-14,943-11,424-14,865-9,720-8,876-5,661-13,093-6,526-4,005-3,775---
  Share Based Compensation6.7%3,2373,0342,3841,7291,4991,2241,02485484532123.00---
Cashflow From Investing-429.7%-13,1303,98315,37514,4864,6458,194-20,399-113,338-56.00--40.00---
Cashflow From Financing-100.0%20.0045,29022335737.00---250128,31054,5147,883---

AVTE Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 16,884$ 10,783$ 46,406$ 26,401
General and administrative4,4843,36912,93710,984
Total operating expenses21,36814,15259,34337,385
Loss from operations(21,368)(14,152)(59,343)(37,385)
Other income (expense):    
Interest income1,8045604,236898
Other income (expense):14(1)(2)
Total other income1,8055644,235896
Net loss(19,563)(13,588)(55,108)(36,489)
Comprehensive loss:    
Net loss(19,563)(13,588)(55,108)(36,489)
Other comprehensive loss:    
Unrealized (loss) gain on securities(22)14243(712)
Comprehensive loss$ (19,585)$ (13,574)$ (54,865)$ (37,201)
Net loss per share, basic$ (0.71)$ (0.56)$ (2.13)$ (1.49)
Net loss per share, diluted$ (0.71)$ (0.56)$ (2.13)$ (1.49)
Weighted-average shares of common stock outstanding, basic27,640,54224,454,78625,872,11824,425,390
Weighted-average shares of common stock outstanding, diluted27,640,54224,454,78625,872,11824,425,390

AVTE Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 32,180$ 22,397
Short-term investments103,019106,823
Prepaid expenses and other current assets2,4042,276
Total current assets137,603131,496
Property and equipment, net316242
Operating lease right-of-use assets7131,003
Other long-term assets2,2442,560
Total assets140,876135,301
Current liabilities:  
Accounts payable3,5042,575
Accrued and other current liabilities10,7704,822
Operating lease liabilities451385
Total current liabilities14,7257,782
Operating lease liabilities, net of current portion358705
Other liabilities7071
Total liabilities15,1538,558
Commitments and contingencies (Note 5) 
Stockholders' equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022, respectively; no shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 27,653,187 and 24,722,974 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively32
Additional paid-in capital268,926215,110
Accumulated other comprehensive loss(195)(466)
Accumulated deficit(143,011)(87,903)
Total stockholders' equity125,723126,743
Total liabilities and stockholders' equity$ 140,876$ 135,301
AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEaerovatetx.com
 EMPLOYEES43

Aerovate Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Aerovate Therapeutics, Inc.? What does AVTE stand for in stocks?

AVTE is the stock ticker symbol of Aerovate Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aerovate Therapeutics, Inc. (AVTE)?

As of Tue Feb 27 2024, market cap of Aerovate Therapeutics, Inc. is 657.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVTE stock?

You can check AVTE's fair value in chart for subscribers.

What is the fair value of AVTE stock?

You can check AVTE's fair value in chart for subscribers. The fair value of Aerovate Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aerovate Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVTE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aerovate Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether AVTE is over valued or under valued. Whether Aerovate Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Aerovate Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVTE.